July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Uveal consequences of CTLA-4 and PD-1 inhibition
Author Affiliations & Notes
  • Martine J. Jager
    Ophthalmology, Leiden University Med Center, Leiden, Netherlands
  • Footnotes
    Commercial Relationships   Martine Jager, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4409. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Martine J. Jager; Uveal consequences of CTLA-4 and PD-1 inhibition. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4409.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Immune checkpoint inhibitors are being used to treat many different types of malignancies, and help patients live longer. As the working mechanism of these inhibitors is de-blocking T cells, this treatment leads to more activity of T cells in general. This leads to many general and ocular side effects.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.